Submit RFP

ICON Biotech will participate in #CTOWC26, the 13th Annual Clinical Trials in Oncology West Coast, taking place on 28–29 April 2026 in Burlingame, California. The event brings together oncology and clinical research pr...

We’re honoured to be recognised for the second consecutive year at the Asia‑Pacific Biopharma Excellence Awards 2026, winning Best Clinical Trial Supplier: Site Innovation. This award reflects the dedication of our APAC...

We’re honoured to receive the Best Clinical Trial Supplier Award: Site Innovation at the Asia‑Pacific Biopharma Excellence Awards 2026 — our second consecutive win. This recognition reflects the commitment of our APAC t...

For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique advantages. Discover how the expected timeframe, type of data needed and study population can play ...

Operationalising NMA in R The paper provides a clear overview of how netmeta and multinma support high quality analyses. – Netmeta enables contrast based, frequentist NMA with automated network construction and heteroge...

The RACE Act changed pediatric oncology in the US. The EMA’s proposed MoA PIP requirements could do the same in Europe. So what does this mean for sponsors? ICON’s Regulatory Affairs (Graham Bell) and Pediatrics (Jacqu...

Proposed requirements for Mechanism of Action based PIPs are coming. Right now, they’re still developing. ICON can help sponsors position to stay ahead of the curve and benefit from incentives while meeting pediatric obl...

As biosimilar portfolios expand, the need for sensitive and reliable bioanalytical methods has never been greater. Our latest spotlight explores evolving approaches that strengthen comparability assessments and support r...

Biosimilar development continues to expand, bringing greater analytical complexity. This spotlight examines the evolving regulatory environment and changing methodologies supporting robust, high confidence bioanalysis. ...

ICON will participate in BIO Korea 2026 from 28 to 30 April in Seoul, South Korea. The event brings together leaders in biotechnology and healthcare to discuss scientific innovation and industry collaboration. Visit ICO...

Strong engagement, open dialogue, and a shared focus on the future. Last week, ICON CEO, Barry Balfe, connected with teams in our São Paulo and Mexico City offices, hosting a series of highly engaged town halls. The vis...

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...